Ferozsons Laboratories Limited FEROZ
Rs 332.00
Vol2,046Updated15:4912 Oct 2026
At a Glance
The headline take on FEROZ — valuation, income, returns, and efficiency
Consolidated snapshot
Price & Performance
Closing prices across timeframes, returns, and range context
FEROZ — Price History
Daily closing series · toggle period below
Key Metrics
Valuation, profitability, structure, and risk in one grid
Dividend History & Yield
Payout track record, yield trend, and upcoming distribution
FEROZ has paid Rs 5.50 per share in cash dividends over the trailing 12 months — a 1.7% yield at the last close. Its most recent payout was Rs 5.50/share, announced 29 Sep 2026 with book closure from 21 Oct 2026. Annual dividend-per-share history back to 2016 is charted below.
Latest Payout
Dividend Per Share Trend
Payout History
Source: PSX company payouts
| Announced | For Period | Type | Amount | Book Closure |
|---|---|---|---|---|
| 29 Sep 2026 | 30 Jun 2026 (YR) | Cash | Rs 5.50(55%) | 21 Oct 2026 – 28 Oct 2026 |
| 23 Sep 2025 | 30 Jun 2025 (YR) | Cash | Rs 4.00(40%) | 18 Oct 2025 – 25 Oct 2025 |
Financials & Earnings
Income, balance sheet, and key ratios from published accounts
FEROZ's market capitalisation stands at Rs 14.27B as of 09 Oct 2026 — down 18.0% over the past 12 months (from Rs 17.41B).
Financial Statements
How FEROZ's income and balance sheet have evolved
| PKR Millions | Mar-26 | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 | Jun-24 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales / Revenue | 5,550 | 6,683 | 5,939 | 4,505 | 5,092 | 4,731 | 4,529 | 3,812 | |
| Cost of Sales | 3,038 | 3,632 | 3,330 | 2,522 | 3,021 | 2,641 | 2,676 | 2,216 | |
| Gross Profit | 2,512 | 3,050 | 2,609 | 1,983 | 2,071 | 2,090 | 1,853 | 1,596 | |
| Administrative Expenses | 275 | 284 | 288 | 211 | 225 | 241 | 225 | 216 | |
| Operating Profit | 527 | 805 | 645 | 623 | 484 | 460 | 575 | 503 | |
| EBITDA | 790 | 1,068 | 903 | 877 | 753 | 674 | 773 | 646 | |
| Other Income | 48 | 51 | 52 | 56 | 80 | 92 | 27 | 47 | |
| Financial Charges | 93 | 98 | 105 | 99 | 110 | 171 | 194 | 220 | |
| Profit Before Tax | 426 | 623 | 539 | 467 | 401 | 327 | 360 | 265 | |
| Taxation | 173 | 278 | 217 | 212 | 153 | 150 | 119 | 70 | |
| Profit After Tax | 253 | 344 | 322 | 255 | 248 | 178 | 241 | 195 | |
| EPS - Basic (Rs) | Rs 4.78 | Rs 6.19 | Rs 5.95 | Rs 4.74 | Rs 4.59 | Rs 3.46 | Rs 5.07 | Rs 4.22 |
Showing 8 of 8 quarters · scroll horizontally to see more periods.
All figures in PKR millions from published accounts.
Profitability & Returns
Margins, returns on capital, and earnings per share
Latest · Mar-26
| Ratio | Value |
|---|---|
| Net profit margin | 4.6% |
| Gross profit margin | 45.3% |
| EBITDA margin | 14.2% |
| EBIT margin | 9.5% |
Net profit margin
Net profit ÷ revenue · %
Financial Health
Coverage, leverage, and the strength of the balance sheet
Latest · Dec-25
| Ratio | Value |
|---|---|
| Current ratio | 1.77 |
| Quick ratio | 0.66 |
| Cash ratio | 0.31 |
| Asset turnover | 0.25x |
| Effective tax rate | 44.6% |
Current ratio
Current assets ÷ current liabilities
Market cap trajectory
Close × current shares outstanding · current Rs 14.27B
Valuation & Capital Returns
What the market is paying for FEROZ, and what it returns to shareholders
Latest · Dec-25
| Ratio | Value |
|---|---|
| Price to earnings | 60.70x |
| Price to book | 1.09x |
| EV / EBITDA | 17.92x |
| Price to sales | 2.44x |
Price to earnings
Period-end price ÷ EPS · times
Technical Analysis
Trading signal, moving averages, momentum, and key levels
10-day SMA (Rs 338.14) is below the 30-day SMA (Rs 342.97). RSI at 43 sits in the neutral band.
Moving AverageThe average close over a set window (10/30/200 days) — smooths daily noise to reveal the trend.Read the full guide →
| Period | Value | vs Current | Position |
|---|---|---|---|
| SMA 10 | Rs 338.14 | +1.85% | Below |
| SMA 30 | Rs 342.97 | +3.30% | Below |
| SMA 60 | Rs 359.25 | +8.21% | Below |
| SMA 200 | Rs 379.80 | +14.40% | Below |
At 43, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.
- MACD-5.50
- Signal-5.96
- Histogram+0.47
Leverage Insights
MTS, margin financing, futures open interest, and combined exposure
Leverage Composition
MTS · MFS stacked over the selected window
No blank sales
No net blank (short) sales reported for FEROZ on the latest PSX DFC report.
Settlement Insights
UIN-wise settlement concentration and price context
Metrics and charts over the selected trailing window
Settlement % Trajectory
Solid = UIN settlement % · Dashed = 14-session EMA
As of 12 Oct 2026
Price vs Settlement
Close price (left axis) · UIN settlement % (right axis)
About the Company
Business description, governance, and corporate information
Ferozsons Laboratories Limited was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is primarily engaged in the imports, manufacture and sale of pharmaceutical products and medical devices.
Corporate Information
- RegistrarCorpTec Associates (Pvt.) Limited, 503-E, Johar Town, Lahore
- AuditorKPMG Taseer Hadi & Co. Chartered Accountants
- Websitewww.ferozsons-labs.com
- AddressFerozsons Laboratories Limited 197-A, The Mall Rawalpindi, Pakistan.
- SectorPharmaceuticals
- Financial Year EndJune
Key People
| Name | Role |
|---|---|
OKOsman Khalid Waheed | CEO |
SGSyed Ghausuddin Saif | Company Secretary |
Reports & Filings
- Quarterly Report — 31 Mar 2026PDF
- Quarterly Report — 31 Dec 2025PDF
- Quarterly Report — 30 Sep 2025PDF
- Quarterly Report — 31 Mar 2025PDF
- Annual Report FY2025PDF
- Quarterly Report — 31 Dec 2024PDF
- Quarterly Report — 30 Sep 2024PDF
- Quarterly Report — 31 Mar 2024PDF
Sourced from official PSX financial-report submissions.
Recent Announcements
Latest company filings as reported on PSX
Filings and disclosures from the PSX announcement feed
- 07 Oct 2026Report
- 07 Oct 2026General Meeting
- 06 Oct 2026General Meeting
- 29 Sep 2026Financial Results
- 22 Sep 2026Board MeetingBoard Meeting
- 17 Sep 2026Material Information
- 15 Jul 2026OtherApproval of Annual Budget for FY 2026-27
- 15 Jul 2026Management ChangeAppointment of Chairperson and Chief Executive Officer
Peers in Pharmaceuticals
How the cohort is moving — same-sector stocks by market cap
FEROZ vs Pharmaceuticals sector median
| Metric | FEROZ | Sector median |
|---|---|---|
| P/E RatioShare price ÷ earnings per share — the price you pay for each rupee of annual profit. Compare within a sector.Read the full guide → | 18.4x | 14.3x |
| Dividend YieldTrailing-12-month cash dividends ÷ share price. A high yield can signal income — or a falling price.Read the full guide → | 1.7% | 3.0% |
| Return on EquityNet profit ÷ shareholders' equity — how hard the company works each rupee investors have put in.Read the full guide → | 5.9% | 22.3% |
| 1-Year Return | -20.0% | -25.7% |
| Market CapitalisationShare price × total shares — the company's full market value, and the basis for index weightings.Read the full guide → | Rs 14.27B | Rs 26.50B |
Pharmaceuticals · sector heat
Why Choose BSL as Your PSX Broker?
Bhayani Securities is an SECP-licensed brokerage and PSX TREC holder with over two decades in Pakistan's stock market. Investors get live prices, research and support in one account.
- Retail Trading
Open a PSX trading account with secure market access and research support.
- Online Trading
Trade on the BSL app with real-time PSX data and portfolio monitoring.
- Margin Financing
Borrow to trade larger positions and increase your buying power.
- Research Reports
Market insights, stock analysis and investing guides from BSL.
- Institutional Services
Research-driven execution, market insights and corporate access for institutions.
- High Net Worth Services
A dedicated senior dealer and preferential rates for portfolios above PKR 2.5 million.
- Trading APIs
Full PSX data, live level-2 market data and sandbox order execution through BSL.
- Roshan Digital Account
Invest in the PSX remotely as an overseas Pakistani.
- Sahulat Account
Start investing with minimal documentation and a fast setup.
- Minor Accounts
Invest for your children and build long-term wealth early.
Frequently Asked Questions
The most common questions investors ask about FEROZ
FEROZ last traded at Rs 332.00, up 1.14% on the day, within a 52-week range of Rs 293.01–475.00. Prices on this page refresh every 15 minutes during market hours; log in to BSL for live quotes.
Ferozsons Laboratories Limited was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. See About the Company on this page for the full profile, management, and corporate information.
FEROZ has paid Rs 5.50 per share in cash dividends over the trailing 12 months — a 1.7% yield at the last close. Review the payout history in the Dividends section and compare with the highest dividend yield stocks on PSX.
FEROZ has announced a payout of Rs 5.50 per share with book closure starting 21 Oct 2026 — you must own the shares before that date to qualify. Track every announcement on the PSX ex-dates calendar.
Yes — Ferozsons Laboratories Limited is on the PSX's Shariah-compliant (KMI All Shares) list. Browse all Shariah-compliant PSX stocks.
FEROZ trades at 18.4x earnings against a Pharmaceuticals median of 14.3x, with a 1.7% dividend yield versus 3.0%. The full comparison table and peer list are in the Peers section, or explore the Pharmaceuticals sector page.
Annual reports for FY2025 are linked under Reports & Filings in the About section of this page, sourced from official PSX submissions.
Open a BSL trading account, fund it, and place your FEROZ order on the Pakistan Stock Exchange — account opening takes minutes online, with PSX execution, research, and concierge support included.
Quotes and metrics refresh on a regular cadence through the trading day and after the close. For streaming real-time PSX prices and order placement, log in to your BSL account.
Ready to invest in FEROZ?
Open a BSL trading account in under 10 minutes
Buy and sell FEROZ and every other PSX-listed stock with low commissions, real-time data, and a concierge research desk backing every trade.